In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Effect of cardiac resynchronization therapy on ventricular tachycardias in patients with dilated cardiomyopathy and severe heart failure

Session Poster session 3

Speaker Denis Lebedev

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : Poster Session
  • FP Number : P1536

Authors : D Lebedev (Tomsk,RU), MV Lebedeva (Tomsk,RU), AI Mishkina (Tomsk,RU), SV Popov (Tomsk,RU)

15 views

Authors:
D Lebedev1 , MV Lebedeva1 , AI Mishkina1 , SV Popov1 , 1Cardiology Research Institute, Tomsk National Research Medical Center of RAS - Tomsk - Russian Federation ,

Citation:

The aim of the study was to elucidate effects of the cardiac resynchronization therapy (CRT) on ventricular tachycardias (VT) in patients with dilated cardiomyopathy (DCM) and to analyze the prospects of the radionuclide diagnostic methods for prediction of the life-threatening arrhythmias. The study included 70 patients aged 32 to 75 years (mean age 55 ± 12 years) with DCM, NYHA  III heart failure, the left ventricular (LV) ejection fraction (EF) of 30.1 ± 3.8%, and end-diastolic volume (EDV) of 220.7 ± 50.9 mL. The first group  included 35 patients (50%) with paroxysms of VT while. The second group  consisted of 35 patients (50%) without VT. After one year of CRT, positive clinical changes were documented in all patients: LV EF increased to 42.8 ± 4.8% (p = 0.001); functional class of heart failure decreased to II; LV EDV decreased to 197.9 ± 47.8 mL (p = 0.005). The patients whose EF increased by 14% and EDV decreased by 35 mL during one-year CRT had no episodes of VT. In patients, with VT  during the entire period of the study  EF increase on 9% and EDV decrease on 13 mL. We also analysed of myocardial metabolism defects (MMD). VT were not registered in patients whose MMD became less than 15% during CRT; if the size of DMM exceeded 15%, paroxysms of VT were observed. Thus, efficacy of CRT in patients with DCM results in a statistically significant reduction of the number of VT. The improvement of the fatty acid metabolism contributes to a decrease in the reduction of VT episodes number during CRT.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are